BB
Therapeutic Areas
Turn Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| GX-03 | Eczema (Atopic Dermatitis) | Phase 1 |
| Unnamed Onychomycosis Program | Onychomycosis | Late-stage clinical |
| Hexagen™ Wound Dressing | Wound Care | Approved/FDA-cleared |
| Thermostable Vaccine Delivery | Infectious Disease (Global Health) | Not specified |
Leadership Team at Turn Therapeutics
DN
Dr. Neil Ghodadra, MD
Chief Medical Officer, Board Director
ZC
Zuraiz Chaudhary, CPA
Chief Accounting Officer, VP Finance
MZ
Muhammad Zubair
Controller
DR
Dr. Robert Redfield, M.D.
Former Director of CDC (External Collaborator/Interview Subject)